Globus Medical
GMED
$74.08
-0.11%
Globus Medical Inc. is a medical device company that develops and manufactures musculoskeletal solutions — primarily spinal and orthopedic implants and instruments — alongside enabling technologies such as surgical navigation and robotic systems used to enhance surgical capabilities. The company operates in the highly competitive medical devices industry, competing against large-cap orthopedic and spine players, and derives the vast majority of its revenue from musculoskeletal products, with more than half generated in the United States. Globus Medical is best characterized as an innovation-driven challenger that has scaled into a top-tier spine player, with its identity increasingly tied to its robotic and navigation platform as a differentiator versus traditional implant-focused competitors. The current investor narrative centers on the company's post-merger integration and revenue acceleration — most recently highlighted by 27% year-over-year revenue growth in the March 2026 quarter — juxtaposed against a sharp stock pullback that has left shares down roughly 16% over the past month and 15% year-to-date despite a positive 1-year return. Debate now hinges on whether the recent margin compression and decelerating momentum are transitory integration costs or signs of structural pressure, with sell-side analysts maintaining a constructive stance even as the market de-rates the stock.…
GMED
Globus Medical
$74.08
Related headlines
Investment Opinion: Should I buy GMED Today?
Rating: Buy. The core thesis is that Globus Medical offers a rare combination of 27% revenue growth, a fortress balance sheet, and a forward PE of 13.72x that is less than half the trailing multiple, creating an asymmetric risk/reward setup anchored by a $103.23 average analyst target (39.4% upside) and a consensus 'buy' rating from 13 analysts. The recent 16% one-month sell-off appears disconnected from fundamental performance, which is why even the lowest analyst target of $84.00 sits 13.4% above the current price.
Supporting evidence is strong across multiple dimensions. Revenue grew 27.04% YoY in Q1 2026 to $759.85 million, with sequential strength from $745.34 million in Q2 2025 to $826.39 million in Q4 2025. Profitability remains solid with a 69.20% gross margin, 21.53% operating margin, and 16.36% net margin in Q1 2026, while trailing free cash flow of $600.32 million and a capital-light model (Q1 2026 capex of $39.62 million) fund growth internally. The balance sheet is pristine with 0.026 debt-to-equity and $560.95 million in cash. Valuation is undemanding: PS of 4.02x and EV/EBITDA of 15.61x are moderate for a 27% grower, and the forward PE of 13.72x is a steep discount to the mid-to-high-20s multiples of large-cap med-tech peers.
The biggest risks that could invalidate this thesis are: (1) failure to achieve the $7.46 forward EPS estimate, which would collapse the forward PE argument; (2) persistent gross margin compression below 65% due to integration costs or mix shift; and (3) a technical breakdown below $73-$74 that opens the path to the $54.15 52-week low. The rating would upgrade to a high-conviction Buy if gross margins stabilize above 70% and forward EPS estimates are confirmed, and would downgrade to Hold if revenue growth decelerates below 15% or if the stock breaks below $70 on volume. Relative to its own history (PS near multi-year lows) and peers (forward PE discount), the stock appears undervalued, though the market is clearly demanding proof of earnings quality before re-rating it.
Sign up to view all
GMED 12-Month Price Forecast
The forward-looking view is cautiously bullish, anchored by 27% revenue growth, a deeply discounted forward PE of 13.72x, and unanimous analyst constructive sentiment with a $103.23 average target. The primary risk is earnings quality: trailing EPS of $0.0456 is distorted by one-time items, and the market is clearly demanding proof that the $7.46 forward estimate is achievable before re-rating the stock. Gross margin volatility (63.28%-72.02% range) and the recent 16% one-month decline suggest the market needs to see clean, margin-expanding quarters. I would upgrade to high confidence if Q3 2026 shows gross margin above 70% and EPS tracking toward the annual estimate, and would downgrade to neutral if revenue growth falls below 15% or the stock breaks below $70 on elevated volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Globus Medical's 12-month outlook, with a consensus price target around $103.23 and implied upside of +39.4% versus the current price.
Average Target
$103.23
0 analysts
Implied Upside
+39.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $125
Analyst target range
Coverage on Globus Medical is solid, with 13 analysts contributing to the consensus. The recommendation distribution skews bullish, with a consensus recommendation of "buy" and a recommendation mean of 1.87 (on a scale where 1 is Strong Buy and 5 is Strong Sell). The average price target is $103.23, which implies approximately 39.4% upside from the current price of $74.08. This is a notably bullish consensus relative to the stock's recent price action, suggesting that analysts view the recent sell-off as overdone and disconnected from fundamental performance.
The target range spans from a low of $84.00 to a high of $125.00 — a spread of $41, or roughly 55% of the low target, indicating meaningful dispersion in analyst views. The low target of $84.00 still implies about 13.4% upside, meaning even the most conservative analyst sees the stock as undervalued at current levels. The high target of $125.00 would require roughly 69% appreciation and likely assumes successful integration of recent acquisitions, sustained 20%+ revenue growth, margin expansion back toward the 70%+ gross margin range, and multiple re-rating as the market regains confidence. Institutional ratings show a stable-to-improving pattern: Needham upgraded from Hold to Buy in January 2026, and firms including RBC Capital, Wells Fargo, Barclays, and Piper Sandler have maintained Outperform/Overweight ratings through mid-2026, with no downgrades evident in the recent data — a signal that the professional community remains constructive despite the stock's technical weakness.
Bulls vs Bears: GMED Investment Factors
The bull case rests on accelerating revenue growth of 27% YoY, a deeply discounted forward PE of 13.72x, a fortress balance sheet with 0.026 debt-to-equity, and analyst targets implying 39% upside; the bear case centers on severe recent underperformance (-16% in one month, -31.6 points vs. SPY over six months), gross margin volatility (63.28%-72.02% range), and technical breakdown risk toward the $54 support. On balance, the fundamental evidence currently favors the bulls, given the revenue trajectory, cash generation, and unanimous analyst constructive stance, but the market is clearly pricing in skepticism about earnings quality and integration execution. The single most important tension is whether the forward EPS estimate of $7.46 is achievable; if it is, the 13.72x forward PE is a glaring mispricing, but if margins and one-time items continue to distort results, the stock could remain de-rated. Resolution likely hinges on the next few quarters showing clean, margin-expanding earnings that validate the forward estimate.
Bullish
- Revenue accelerating at 27% YoY: Q1 2026 revenue of $759.85 million grew 27.04% versus Q1 2025's $598.12 million, and the multi-quarter trend shows consistent sequential strength from $745.34 million in Q2 2025 to $826.39 million in Q4 2025. This growth rate is well above the typical mid-single-digit to low-double-digit growth of large-cap orthopedic peers, suggesting Globus is taking share in spine.
- Forward PE of 13.7x is deeply discounted: The stock trades at a trailing PE of 21.94x but a forward PE of just 13.72x, implying the market expects earnings to more than double to the consensus EPS estimate of $7.46. This forward multiple is a steep discount to the mid-to-high-20s PE typically commanded by large-cap medical device peers, creating potential for multiple re-rating if execution continues.
- Analyst targets imply 39% upside: The 13-analyst consensus average target price is $103.23, roughly 39.4% above the current $74.08, with a consensus recommendation of 'buy' and a recommendation mean of 1.87. Even the lowest target of $84.00 implies 13.4% upside, meaning no covering analyst sees the stock as overvalued at current levels.
- Fortress balance sheet with 0.026 D/E: Debt-to-equity of just 0.026, a current ratio of 4.26, and $560.95 million in cash give Globus substantial flexibility to fund acquisitions (it deployed $247.31 million in Q4 2025) and buybacks without financial strain. Free cash flow of $600.32 million TTM and a capital-light model (Q1 2026 capex of only $39.62 million) mean growth is internally funded.
Bearish
- Severe recent underperformance vs. market: The stock is down 16.14% over the past month and 15.14% year-to-date, underperforming SPY by 15.18 percentage points over one month and 31.56 points over six months. This divergence from a positive 1-year return of 30.54% signals a trend reversal or deep repricing rather than simple consolidation.
- Gross margin volatility raises concerns: Gross margin has swung from 72.02% in Q4 2025 to 63.28% in Q3 2025 to 69.20% in Q1 2026, suggesting mix shifts and integration-related cost dynamics. The Q2 2025 net income spike to $202.85 million (27.22% net margin) was inflated by a $112.06 million other-income item, meaning underlying earnings power is closer to the mid-to-high teens net margin range.
- Earnings quality distortion from one-time items: Trailing EPS of $0.0456 is distorted by non-recurring items, including a $112.06 million other-income boost in Q2 2025 and a $106.75 million other-expense drag in Q4 2025. The PEG ratio of 0.052 is therefore unreliable, and the true earnings base is harder to assess than headline figures suggest.
- Technical breakdown below key support: At $74.08, the stock sits at roughly 43% of its 52-week range ($54.15 low, $101.40 high) and has a maximum drawdown of 24.02%. A breakdown below the $73-$74 area would open the door toward the $54 support zone, roughly 27% below current levels, likely confirming the downtrend.
GMED Technical Analysis
Globus Medical is in a medium-term downtrend within a longer-term recovery structure. The stock is up 30.54% over the past year, but that gain masks a deteriorating trajectory: shares have fallen 14.12% over six months and 15.14% year-to-date. At a current price of $74.08, the stock sits at roughly 43% of its 52-week range (52-week low of $54.15, high of $101.40), meaning it is trading in the lower half of its annual band and closer to the lows than the highs — a positioning that signals fading momentum and raises the question of whether this is a value opportunity or a falling knife. The 24.02% maximum drawdown confirms the stock has experienced a meaningful correction from its peak.
Short-term momentum is clearly negative and diverging from the longer-term trend. The stock is down 16.14% over the past month and 6.50% over three months, while the 1-year change remains positive at 30.54%. This divergence — a positive annual return colliding with a sharply negative recent trend — typically signals either a trend reversal or a deep mean-reversion pullback, and the magnitude of the 1-month decline suggests the market is repricing the stock rather than simply consolidating. Relative strength metrics reinforce the weakness: the stock has underperformed SPY by 15.18 percentage points over the past month and by 31.56 percentage points over six months, even as it outperformed by 15.53 points over the full year. Volume of approximately 2.9 million shares and a short ratio of 4.95 days indicate moderate but not extreme bearish positioning.
Key technical levels are well defined. Support sits near the 52-week low of $54.15, roughly 27% below the current price, while resistance is anchored at the 52-week high of $101.40, about 37% above. A breakdown below the recent $73–$74 area would open the door toward the $54 support zone and likely confirm the downtrend, whereas a reclaim of the $85–$88 region would be the first sign of stabilization. With a beta of 0.956, the stock is slightly less volatile than the broader market, meaning its recent underperformance is driven by stock-specific factors rather than amplified market beta — an important consideration for position sizing, as the risk here is idiosyncratic rather than systemic.
Beta
0.96
0.96x market volatility
Max Drawdown
-24.0%
Largest decline past year
52-Week Range
$54-$101
Price range past year
Annual Return
+30.5%
Cumulative gain past year
| Period | GMED Return | S&P 500 |
|---|---|---|
| 1m | -16.1% | -0.5% |
| 3m | -6.5% | +2.3% |
| 6m | -14.1% | +16.6% |
| 1y | +30.5% | +14.8% |
| ytd | -15.1% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GMED Fundamental Analysis
Globus Medical's revenue trajectory remains robust, even as the stock has faltered. The most recent quarter (Q1 2026, ended March 31, 2026) delivered revenue of $759.85 million, representing 27.04% year-over-year growth versus the $598.12 million reported in Q1 2025. The multi-quarter trend shows consistent sequential strength: revenue rose from $745.34 million in Q2 2025 to $769.05 million in Q3 2025 and $826.39 million in Q4 2025 before the seasonal dip to $759.85 million in Q1 2026 — a pattern that reflects healthy underlying demand rather than deceleration. Segment data shows the Spine business generating $741.01 million against $28.04 million from Emerging Technology, confirming that the core implant franchise is the primary growth engine while the enabling-technology platform remains a smaller but strategically important contributor.
Profitability is solid but shows signs of margin variability. Net income in Q1 2026 was $124.30 million on a net margin of 16.36%, with gross margin at 69.20% and operating margin at 21.53%. Gross margin has fluctuated meaningfully across recent quarters — from 72.02% in Q4 2025 to 63.28% in Q3 2025 to 69.20% in Q1 2026 — suggesting mix shifts and integration-related cost dynamics. The company's trailing net margin of 18.30% and operating margin of 16.33% are respectable for the medical device industry, though the Q2 2025 spike in net income to $202.85 million (27.22% net margin) was inflated by a large other-income item of $112.06 million, underscoring that underlying earnings power is more consistent with the mid-to-high teens net margin range.
The balance sheet is exceptionally strong. Debt-to-equity stands at just 0.026, with a current ratio of 4.26 and a cash balance of $560.95 million at the end of Q1 2026. Free cash flow on a trailing-twelve-month basis is $600.32 million, and Q1 2026 free cash flow was $162.75 million on operating cash flow of $202.36 million, with capital expenditures of only $39.62 million — a capital-light model that funds growth internally. ROE of 11.76% and ROA of 8.74% are healthy, and the company carries no meaningful debt burden, giving it substantial flexibility for acquisitions (it deployed $247.31 million on acquisitions in Q4 2025) and share repurchases without financial strain.
Quarterly Revenue
$759854000.0B
2026-03
Revenue YoY Growth
+27.0%
YoY Comparison
Gross Margin
69.2%
Latest Quarter
Free Cash Flow
$600320000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GMED Overvalued?
Because Globus Medical is profitable — Q1 2026 net income of $124.30 million and trailing EPS of $0.0456 — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 21.94x and a forward PE of just 13.72x, a remarkably wide gap that implies the market expects earnings to more than double over the next year. This gap is consistent with the analyst consensus EPS estimate of $7.46 for the forward period, which, if achieved, would represent a dramatic earnings inflection from the current trailing level. The PEG ratio of 0.052 is extraordinarily low, though it should be treated with caution given the distortion from the near-zero trailing EPS figure.
Relative to the broader medical devices sector, Globus Medical screens as reasonably valued on most metrics. Its PS ratio of 4.02x and EV/Sales of 3.01x are moderate for a company growing revenue at 27%, and its EV/EBITDA of 15.61x is not stretched for a med-tech franchise with mid-teens operating margins. The PB ratio of 2.58x is modest given the company's asset-light model and strong ROE. On a forward basis, the 13.72x PE represents a discount to the typical mid-to-high-20s multiple commanded by large-cap medical device peers, suggesting the market is pricing in skepticism about the durability of the earnings recovery — a discount that could narrow if execution continues.
Historically, Globus Medical has traded at significantly richer multiples. The stock's PS ratio has ranged from over 32x in early 2022 to around 10x in mid-2025, and its PE has swung from over 100x in periods of depressed earnings to the low-20s today. The current PS of 4.02x is near the low end of its multi-year band, and the PB of 2.58x is well below the 4.0x+ levels seen in 2021–2022. This places the stock near the bottom of its own historical valuation range, which could signal either a compelling value opportunity or a market that has permanently de-rated the name due to competitive and integration concerns — the resolution of which will depend on whether revenue growth and margins can be sustained.
PE
21.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~109x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.6x
Enterprise Value Multiple
Investment Risk Disclosure
Globus Medical's financial risks are relatively contained but not negligible. The company carries minimal debt (debt-to-equity of 0.026) and has $560.95 million in cash with a current ratio of 4.26, so solvency is not a concern. However, earnings quality is a real issue: Q2 2025 net income of $202.85 million was inflated by a $112.06 million other-income item, and Q4 2025 included a $106.75 million other-expense drag, meaning the trailing EPS of $0.0456 and the resulting 21.94x trailing PE are distorted. Gross margin volatility (63.28% in Q3 2025 vs. 72.02% in Q4 2025) also signals integration-related cost pressures that could persist if acquisition synergies disappoint. Revenue concentration in the Spine segment ($741.01 million of $759.85 million in Q1 2026) means any slowdown in spinal implant demand or reimbursement changes would hit the top line disproportionately.
Market and competitive risks are elevated given the stock's recent technical breakdown and premium-sensitive positioning. The stock has underperformed SPY by 31.56 percentage points over six months and trades at roughly 43% of its 52-week range, reflecting a market that is actively de-rating the name despite 27% revenue growth. With a beta of 0.956, the stock is slightly less volatile than the market, so the underperformance is idiosyncratic rather than systemic, which cuts both ways: it means the sell-off is company-specific and could reverse on execution, but it also means there is no macro tailwind to rely on. Competitive pressure from larger orthopedic and spine players remains intense, and the Emerging Technology segment at only $28.04 million in quarterly revenue is too small to offset a core franchise slowdown. Recent news flow has been mixed, with sector peers like CooperCompanies missing revenue on destocking, highlighting inventory and demand risks across medical devices.
The worst-case scenario would involve a combination of slowing spine growth, persistent gross margin compression below 65%, and failure to achieve the $7.46 forward EPS estimate, which would invalidate the 13.72x forward PE thesis and force a re-rating toward the trailing multiple. In that scenario, the stock could retest its 52-week low of $54.15, representing roughly 27% downside from the current $74.08, and the maximum drawdown of 24.02% shows this magnitude of decline is realistic. The analyst low target of $84.00 provides some cushion, but if estimates are cut, that floor would likely move lower. An investor could realistically lose 20-27% from current levels in an adverse scenario, with the $54-$60 zone as the key downside reference.
FAQ
The most severe risk is earnings quality and estimate risk: trailing EPS of $0.0456 is distorted by one-time items, and failure to achieve the $7.46 forward EPS estimate would collapse the 13.72x forward PE thesis and likely trigger a re-rating toward the trailing multiple. Second is margin risk, with gross margin swinging from 72.02% in Q4 2025 to 63.28% in Q3 2025, indicating integration-related cost pressures that could persist. Third is technical and momentum risk, as the stock is down 16.14% over one month, trades at only 43% of its 52-week range, and a break below $73-$74 could target the $54.15 low, roughly 27% downside. Fourth is competitive and concentration risk, with the Spine segment generating $741.01 million of $759.85 million in Q1 2026 revenue, leaving the company heavily dependent on a single franchise facing large orthopedic competitors.
The 12-month forecast has three scenarios: a base case (50% probability) targeting $84-$103 as revenue growth moderates to the high-teens and margins stabilize, a bull case (30% probability) targeting $103-$125 if the $7.46 EPS estimate is achieved and the multiple re-rates toward peers, and a bear case (20% probability) targeting $54-$84 if growth decelerates below 15% and estimates are cut. The base case is most likely, assuming gross margin holds between 67% and 70% and no major competitive disruption occurs. The key assumption behind the base case is that the forward EPS estimate is broadly achievable, which would validate the current 13.72x forward PE and allow the stock to recover toward the $103.23 analyst average target. The bear case is anchored by the $54.15 52-week low and the analyst low target of $84.00.
GMED appears undervalued on forward metrics but fairly valued to slightly cheap on trailing metrics. The forward PE of 13.72x is a steep discount to the mid-to-high-20s multiples typical of large-cap medical device peers, while the trailing PE of 21.94x is moderate for a company growing revenue at 27%. The PS ratio of 4.02x and EV/EBITDA of 15.61x are reasonable for a med-tech franchise with 69.20% gross margins, and the PS ratio sits near the low end of a multi-year band that ranged from over 32x in early 2022 to around 10x in mid-2025. The market is clearly pricing in skepticism about the $7.46 forward EPS estimate, as evidenced by the wide gap between trailing and forward multiples. If that estimate is achieved, the stock is significantly undervalued; if it is cut, the current price may be fair or even rich relative to revised earnings.
From a risk/reward perspective, GMED offers an attractive setup with 39.4% upside to the $103.23 average analyst target against roughly 27% downside to the $54.15 52-week low, a favorable asymmetry supported by 27.04% YoY revenue growth and a 13.72x forward PE. The consensus 'buy' rating from 13 analysts and the fact that even the lowest target ($84.00) implies 13.4% upside suggest the professional community views the recent sell-off as overdone. However, the stock is in a clear downtrend, down 16.14% over one month and underperforming SPY by 31.56 points over six months, so timing risk is real. It is a good buy for patient investors with a 12-24 month horizon who can withstand a potential retest of the $54-$60 zone, but less suitable for short-term traders given the negative momentum. The key condition is confirmation of earnings quality in the next quarterly report.
GMED is better suited for long-term investment with a minimum suggested holding period of 12-24 months. The company pays no dividend (payout ratio of 0), so returns depend entirely on capital appreciation, and the growth story requires time for integration costs to normalize and earnings quality to be proven. The beta of 0.956 indicates slightly below-market volatility, but the 24.02% maximum drawdown and 16.14% one-month decline show the stock can be volatile in the short term, making it unsuitable for traders seeking stability. Earnings visibility is moderate: revenue growth is consistent at 27% YoY, but margin volatility and one-time items reduce near-term predictability. Long-term holders can look through the current de-rating toward the 39.4% upside implied by analyst targets, while short-term traders face significant timing risk given the negative momentum and technical breakdown below key support.